Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study
Authors:ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author)
Files:.pdf PDF - Presentation file, download (1,58 MB)
MD5: E5B817D1334C093553F6EC429C0A7178
 
.pdf PDF - Supplement, download (1,10 MB)
MD5: C384BC86E3FD51111A4BAD50BC370759
 
URL URL - Source URL, visit https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
Keywords:non-small cell lung carcinoma -- therapy, drug therapy, afatinib, osimertinib, GioTag study
Year of publishing:2020
Publication status in journal:In print
Article version:Publisher's version of article
Publisher:Future Medicine Ltd
Number of pages:str. [1-10]
Numbering:Vol. 16, no.
Source:Velika Britanija
UDC:616-006
ISSN on article:1744-8301
DOI:10.2217/fon-2020-0740 New window
COBISS.SI-ID:37424899 New window
Copyright:© 2020 Maximilian J. Hochmair and other authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 14. 11. 2020; Soavtorica iz Slovenije: Tanja Cufer;
Publication date in DiRROS:18.11.2020
Views:900
Downloads:643
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
  
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Future oncology
Publisher:Future Medicine
ISSN:1744-8301
COBISS.SI-ID:521824025 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:28.08.2020

Secondary language

Language:Undetermined
Keywords:nedrobnocelični karcinom pljuč -- terapija, terapija z zdravili, afatinib, osimertinib, raziskava GioTag


Back